Clinical Trial Update: Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating BAFF-R CAR-T cell therapy for refractory neuroimmune diseases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Inflammatory Demyelinating Polyneuropathy
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• BAFF-R CAR-T (BAFF receptor-targeted chimeric antigen receptor T cell therapy)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1, Phase 2 | Status: RECRUITING